Company Profile

Nano Interface Technology Inc (AKA: NITI)
Profile last edited on: 8/30/2023      CAGE: 1M0C9      UEI:

Business Identifier: Nanotechnology-derived economical ultra-pure coatings for orthopedic and dental implants
Year Founded
1998
First Award
1998
Latest Award
2006
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

8390 Terminal Road Suite A
Lorton, VA 22079
   (703) 339-2929
   niti@nanointerfacetech.com
   www.nanointerfacetech.com
Location: Single
Congr. District: 08
County: Fairfax

Public Profile

Nano Interface Technology, Inc. (NITI) is involved in development of novel nanotechnologies in biotechnology, material sciences and the drug delivery areas. One of the major scientific challenges for the material scientists has been the development of processes that can help control the ultra-homogeneity in material properties at a molecular stage. The firm are able to ynthesize molecules under highly controlled conditions for specific applications. With the right reaction system and specific ambient conditions, can control the properties and purity levels of products. All of these processes can be scaled up for large-scale production, at commercial levels. Vision is to significantly alter the processes and purity levels of materials by creating them at the molecular level.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2006 2 NIH $373,279
Project Title: Nano-Apatite Coating of the Porous Surface of Implants
2002 1 NSF $100,000
Project Title: Microemulsion-based Nanoencapsulates of the Anticancer Drugs
2002 1 AF $100,000
Project Title: Microemulsion-based Nanoencapsulates of the Anticancer Drugs
2002 1 NSF $100,000
Project Title: Microemulsion-based Nanoencapsulates of the Anticancer Drugs
2002 1 CBD $69,336
Project Title: Self-Assembly Assisted Production of Nontoxic Obscurants

Key People / Management

  Chittaranjan P Singh -- President

  K L Mittal -- chief scientific advisor

  Maya Sinha -- Vive President and co-founder

  John Texter

Company News

There are no news available.